Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, a once-nightly oxybate product; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-860-0045
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$10.51 million
Profitability
Miscellaneous
Employees71
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Concert Pharmaceuticals (NASDAQ:CNCE) Frequently Asked Questions
What is Concert Pharmaceuticals' stock symbol?
Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."
How were Concert Pharmaceuticals' earnings last quarter?
Concert Pharmaceuticals Inc (NASDAQ:CNCE) released its quarterly earnings data on Thursday, August, 1st. The biotechnology company reported ($0.78) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.92) by $0.14. The biotechnology company had revenue of $0.05 million for the quarter, compared to analysts' expectations of $0.30 million. Concert Pharmaceuticals had a negative net margin of 7,303.34% and a negative return on equity of 49.44%. View Concert Pharmaceuticals' Earnings History.
When is Concert Pharmaceuticals' next earnings date?
What price target have analysts set for CNCE?
7 Wall Street analysts have issued 12-month price objectives for Concert Pharmaceuticals' shares. Their forecasts range from $13.00 to $30.00. On average, they anticipate Concert Pharmaceuticals' stock price to reach $21.2857 in the next twelve months. This suggests a possible upside of 105.7% from the stock's current price. View Analyst Price Targets for Concert Pharmaceuticals.
What is the consensus analysts' recommendation for Concert Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Concert Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Concert Pharmaceuticals.
What are Wall Street analysts saying about Concert Pharmaceuticals stock?
Here are some recent quotes from research analysts about Concert Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small molecule drugs. The Company manufactures drugs in various therapeutic areas such as hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, and schizophrenia, multiple tumors, and hyperparathyroidism. Concert Pharmaceuticals Inc. is based in United States. " (8/7/2019)
- 2. HC Wainwright analysts commented, "Our price target of $29/share is comprised of $10.39 from CTP-543 in AA + $3.81 from AVP-786 in AD + $8.60 in schizophrenia + $5.75 in cash and is based on a discounted cash flow analysis (2019-2026) using a 12% discount rate and 1% growth rate, in line with the expected discount and growth parameters of a development stage biotechnology company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) smaller than anticipated commercial opportunity due to market size, competition, and pricing." (8/2/2019)
- 3. Mizuho analysts commented, "We do not see earnings as the most meaningful indicator of value for developmental stage biotechs. Catalysts to watch: 1) CTP-543 Phase II data for alopecia areata (AA) is expected in 3Q19, 2) AVP-786 second Phase III trial is expected to complete in Dec 2019, data could be available in early 2020. Concert had $153.8mn at the end of 1Q19 which is expected to support operation through 2H20." (5/3/2019)
Has Concert Pharmaceuticals been receiving favorable news coverage?
News coverage about CNCE stock has been trending positive recently, according to InfoTrie. The research group rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Concert Pharmaceuticals earned a coverage optimism score of 2.5 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the next several days. View News Stories for Concert Pharmaceuticals.
Are investors shorting Concert Pharmaceuticals?
Concert Pharmaceuticals saw a decline in short interest in the month of July. As of July 31st, there was short interest totalling 866,600 shares, a decline of 6.6% from the June 30th total of 928,100 shares. Based on an average daily trading volume, of 198,600 shares, the short-interest ratio is presently 4.4 days. Approximately 4.5% of the shares of the company are sold short. View Concert Pharmaceuticals' Current Options Chain.
Who are some of Concert Pharmaceuticals' key competitors?
Some companies that are related to Concert Pharmaceuticals include Dicerna Pharmaceuticals (DRNA), Omeros (OMER), Y-mAbs Therapeutics (YMAB), Cara Therapeutics (CARA), Spectrum Pharmaceuticals (SPPI), Principia Biopharma (PRNB), Emisphere Technologies (EMIS), Axsome Therapeutics (AXSM), ANI Pharmaceuticals (ANIP), ZIOPHARM Oncology (ZIOP), Vanda Pharmaceuticals (VNDA), Kura Oncology (KURA), Arvinas (ARVN), OrganiGram (OGI) and Alder Biopharmaceuticals (ALDR).
What other stocks do shareholders of Concert Pharmaceuticals own?
Who are Concert Pharmaceuticals' key executives?
Concert Pharmaceuticals' management team includes the folowing people:
- Mr. Richard H. Aldrich Mba, Co-Founder & Chairman (Age 65)
- Dr. Roger D. Tung, Co-Founder, CEO, Pres & Director (Age 59)
- Ms. Nancy Stuart, Chief Operating Officer (Age 61)
- Dr. James V. Cassella, Chief Devel. Officer (Age 64)
- Mr. Marc A. Becker, Chief Financial Officer (Age 47)
Who are Concert Pharmaceuticals' major shareholders?
Concert Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.13%), Ingalls & Snyder LLC (5.71%), Vanguard Group Inc. (4.24%), Bank of America Corp DE (3.20%), Renaissance Technologies LLC (2.59%) and Nuveen Asset Management LLC (1.93%). Company insiders that own Concert Pharmaceuticals stock include Bvf Partners L P/Il, James V Cassella, Nancy Stuart, Peter Barton Hutt, Richard Aldrich, Ronald W Barrett, Ryan Lynch and Value Fund L P Biotechnology. View Institutional Ownership Trends for Concert Pharmaceuticals.
Which major investors are selling Concert Pharmaceuticals stock?
CNCE stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Renaissance Technologies LLC, BlackRock Inc., Connor Clark & Lunn Investment Management Ltd., Bank of New York Mellon Corp, Alps Advisors Inc., Invesco Ltd. and Trexquant Investment LP. Company insiders that have sold Concert Pharmaceuticals company stock in the last year include Bvf Partners L P/Il and Peter Barton Hutt. View Insider Buying and Selling for Concert Pharmaceuticals.
Which major investors are buying Concert Pharmaceuticals stock?
CNCE stock was purchased by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Nuveen Asset Management LLC, Prudential Financial Inc., Ingalls & Snyder LLC, Marshall Wace LLP, Panagora Asset Management Inc., AXA and International Biotechnology Trust PLC. Company insiders that have bought Concert Pharmaceuticals stock in the last two years include Richard Aldrich and Value Fund L P Biotechnology. View Insider Buying and Selling for Concert Pharmaceuticals.
How do I buy shares of Concert Pharmaceuticals?
Shares of CNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Concert Pharmaceuticals' stock price today?
One share of CNCE stock can currently be purchased for approximately $10.35.
How big of a company is Concert Pharmaceuticals?
Concert Pharmaceuticals has a market capitalization of $246.33 million and generates $10.51 million in revenue each year. The biotechnology company earns $-56,020,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis. Concert Pharmaceuticals employs 71 workers across the globe.View Additional Information About Concert Pharmaceuticals.
What is Concert Pharmaceuticals' official website?
How can I contact Concert Pharmaceuticals?
Concert Pharmaceuticals' mailing address is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-860-0045 or via email at [email protected]
MarketBeat Community Rating for Concert Pharmaceuticals (NASDAQ CNCE)
MarketBeat's community ratings are surveys of what our community members think about Concert Pharmaceuticals and other stocks. Vote "Outperform" if you believe CNCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
